As the first two programs targeting the helicase WRN enter the clinic for MSI+ cancers, they set up a comparison of different inhibitory mechanisms
Product Development
Product Development
An explosion of CAR T applications among key themes at this year’s ASGCT meeting
Deals
Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more
Management Tracks
Plus: Radiotherapy play Ratio gets new COO, CFO; and updates from Araceli, Kezar and Hercules
BioCentury ISSN 1097-7201